Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Genetic Signatures Limited (GSS.AX)
AUD0.06
+0.00 (+0.00%)
AU ASX Healthcare Medical - Diagnostics & Research
Address
Heart Research Institute 2042
Newtown, NSW, AU
Newtown, NSW, AU
CEO
Maria Halasz
Website
geneticsignatures.com
IPO
2015-03-30
ISIN AU000000GSS4
Description
Genetic Signatures Limited operates as a molecular diagnostics (MDx) enterprise, extending its reach across Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. The company engineers and manufactures an array of real-time Polymerase Chain Reaction (PCR)-based products, sold under the EasyScreen brand, for the identification of infectious diseases. Moreover, it offers its proprietary MDx 3Base platform technology, enabling hospitals and pathology laboratories to conduct comprehensive screenings for diverse infectious pathogens. Its offerings also encompass detection kits tailored for conditions such as gastrointestinal ailments, respiratory illnesses, sexual health concerns, antimicrobial resistance, meningitis, and tropical diseases. Founded in 2001, the firm is headquartered in Newtown, Australia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD0.06
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.54
Float Shares
174.89M
Free Float %
77.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -6.76% | -15.85% | -31.00% | -76.21% | -72.40% | -85.63% | -88.23% | -93.78% | -84.30% | -85.43% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.06
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | -1 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-1.68
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%+62.8% ★ Q4'25: +140.9% (vs Q4'23)
-
EPS growth Medical - Diagnostics & Research: +30.8%+19.4% Q4'25: +61.6% (vs Q4'23)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-99.2% Q4'25: -10.9% (vs Q4'23)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-116.2% Q4'25: -101.9% (vs Q4'23)
-
ROIC Medical - Diagnostics & Research: +5.2%-94.3% Q4'25: -181.3% (vs Q4'23)
-
Share dilution Medical - Diagnostics & Research: 0.0%+37.2% Q4'25: +58.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-0.05× Q4'25: -0.02× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
Jun 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.04M
est: 800.0K (+30.4%)
|
3.27M
est: 2.00M (+63.3%)
|
4.06M
est: 8.00M (-49.2%)
|
4.99M
est: 14.30M (-65.1%)
|
7.02M
est: 22.40M (-68.6%)
|
11.26M
est: 13.60M (-17.2%)
|
28.28M
est: 28.00M (+1.0%)
|
35.42M
est: 35.40M (+0.1%)
|
16.94M
est: 17.10M (-0.9%)
|
9.77M
est: 9.80M (-0.3%)
|
15.90M
est: 15.90M (+0.0%)
|
18.20M
18.20M – 18.20M
+14.5% YoY
|
21.80M
21.80M – 21.80M
+19.8% YoY
|
26.00M
26.00M – 26.00M
+19.3% YoY
|
141.60M
141.60M – 141.60M
+444.6% YoY
|
| EBITDA |
-2.38M
est: -404.7K (-488.1%)
|
-2.60M
est: -1.01M (-156.9%)
|
-2.30M
est: -4.05M (+43.1%)
|
-2.77M
est: -7.23M (+61.8%)
|
-3.02M
est: -11.33M (+73.3%)
|
-1.17M
est: -6.88M (+83.0%)
|
3.22M
est: -14.16M (+122.7%)
|
4.70M
est: -17.91M (+126.2%)
|
-13.14M
est: -5.49M (-139.5%)
|
-19.82M
est: -4.96M (-299.9%)
|
-16.08M
est: -8.04M (-99.9%)
|
-9.21M
-9.21M – -9.21M
-14.5% YoY
|
-11.03M
-11.03M – -11.03M
-19.8% YoY
|
-13.15M
-13.15M – -13.15M
-19.3% YoY
|
-71.63M
-71.63M – -71.63M
-444.6% YoY
|
| EBIT |
-2.66M
est: -434.5K (-512.0%)
|
-3.03M
est: -1.09M (-178.6%)
|
-3.19M
est: -4.34M (+26.6%)
|
-3.25M
est: -7.77M (+58.1%)
|
-3.49M
est: -12.16M (+71.3%)
|
-2.05M
est: -7.39M (+72.2%)
|
1.79M
est: -4.87M (+136.8%)
|
3.08M
est: -19.22M (+116.0%)
|
-14.05M
est: -4.88M (-187.7%)
|
-21.82M
est: -5.32M (-310.0%)
|
-18.48M
est: -8.63M (-114.0%)
|
-9.88M
-9.88M – -9.88M
-14.5% YoY
|
-11.84M
-11.84M – -11.84M
-19.8% YoY
|
-14.12M
-14.12M – -14.12M
-19.3% YoY
|
-76.90M
-76.90M – -76.90M
-444.6% YoY
|
| Net Income |
-2.66M
est: -12.62M (+78.9%)
|
-3.03M
est: -6.20M (+51.2%)
|
-2.67M
est: 5.31M (-150.3%)
|
-3.25M
est: 13.73M (-123.7%)
|
-3.49M
est: 28.12M (-112.4%)
|
-2.09M
est: -3.76M (+44.6%)
|
1.76M
est: -5.07M (+134.7%)
|
3.06M
est: 4.87M (-37.1%)
|
-14.05M
est: -5.08M (-176.5%)
|
-17.86M
est: -17.86M (+0.0%)
|
-20.10M
est: -20.10M (+0.0%)
|
-17.91M
-17.91M – -17.91M
+10.9% YoY
|
-10.43M
-10.43M – -10.43M
+41.8% YoY
|
-6.12M
-6.12M – -6.12M
+41.3% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
2.37M
est: 504.5K (+370.2%)
|
4.21M
est: 1.26M (+233.6%)
|
3.91M
est: 5.05M (-22.5%)
|
4.81M
est: 9.02M (-46.7%)
|
5.71M
est: 14.13M (-59.6%)
|
2.47M
est: 8.58M (-71.3%)
|
2.84M
est: 18.07M (-84.3%)
|
4.26M
est: 22.33M (-80.9%)
|
6.30M
est: 10.78M (-41.5%)
|
15.14M
est: 6.18M (+144.9%)
|
16.07M
est: 10.03M (+60.2%)
|
11.48M
11.48M – 11.48M
+14.5% YoY
|
13.75M
13.75M – 13.75M
+19.8% YoY
|
16.40M
16.40M – 16.40M
+19.3% YoY
|
89.30M
89.30M – 89.30M
+444.6% YoY
|
| EPS |
-0.05
est: -0.06 (+5.7%)
|
-0.04
est: -0.03 (-53.6%)
|
-0.03
est: 0.02 (-218.6%)
|
-0.03
est: 0.06 (-151.7%)
|
-0.03
est: 0.12 (-126.4%)
|
-0.02
est: -0.02 (+3.0%)
|
0.01
est: 0.01 (+22.9%)
|
0.02
est: 0.02 (-2.7%)
|
-0.10
est: -0.10 (+2.0%)
|
-0.11
est: -0.08 (-41.0%)
|
-0.09
est: -0.09 (+0.9%)
|
-0.08
-0.08 – -0.08
+11.7% YoY
|
-0.05
-0.05 – -0.05
+41.8% YoY
|
-0.03
-0.03 – -0.03
+41.3% YoY
|
—
— – —
+100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-24.06M
OE per share TTM
-0.11
Owner's Yield
-153.53%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
32.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-158.0K
Shares Outstanding
227.14M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Maria Halasz | Chief Executive Officer | 796.6K | female |
| Michael Anton Aicher | Executive Director of US Operations & Executive Director | 185.6K | male |
| Anne Nicole Lockwood | Interim MD & Director | 56.0K | female |
| Christopher Abbott | Founder & Chairman Emeritus | — | male |
| Angela Wang | Financial Controller | — | female |
| Rebecca Abbatantuono | Chief People Officer | — | female |
| Susanne K. Pedersen | Chief Technology Officer | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GSS.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
